# EXL01 in Combination With Nivolumab for Advanced NSCLC Refractory to Immunotherapy.

Source: https://onco.cc/trials/nct06448572/  
OnCo record `nct06448572` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial in lung cancer, run by University Hospital, Lille, now recruiting.

## Summary

EXL01 in Combination With Nivolumab for Advanced NSCLC Refractory to Immunotherapy. is a phase 1/2, interventional study registered as NCT06448572 by University Hospital, Lille, with a registry enrolment figure of 21 participants, started 2024-07-16 and due to reach its primary completion in 2028-10-01. Interventions recorded: EXL01. Conditions listed: Non-Small Cell Lung Cancer. Primary outcome: Progression-free survival rate (PFS Rate) for the assessment of efficacy, defined as the rate of alive and non-progressive subjects as per iRECIST 1.1 over the study subjects.. Lung eligibility wording from the registry: "Histologically or cytologically documented inoperable advanced/metastatic NSCLC". Sites: France. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-25
- Also known as: EXLIBRIS
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT06448572
- Phase: 1/2
- Setting: EXL01 in Combination With Nivolumab for Advanced NSCLC Refractory to Immunotherapy
- Sponsor: University Hospital, Lille
- Enrolled: 21

## Sources

- ClinicalTrials.gov NCT06448572: https://clinicaltrials.gov/study/NCT06448572

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06448572.json